Trial Profile
Phase I single ascending dose trial of Z 944.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Jun 2012
Price :
$35
*
At a glance
- Drugs Ulixacaltamide (Primary)
- Indications Pain
- Focus Adverse reactions
- 19 Jun 2012 The primary endpoint, 'Maximum tolerated dose', has been met, according to a Zalicus media release.
- 19 Jun 2012 Status changed from recruiting to completed.
- 03 May 2012 Location changed from USA to United Kingdom, according to a Zalicus media release.